ANSWER: B

Rationale:

Aspirin's defining pharmacodynamic property is irreversible covalent acetylation of a serine residue (Ser530 of COX-1, Ser516 of COX-2) at the enzyme's active site. This covalent modification permanently inactivates both COX isoforms for the lifetime of the affected cell. In anucleate platelets, which cannot synthesize new protein, a single dose of aspirin abolishes COX-1-dependent thromboxane A2 production for the entire 8- to 10-day platelet lifespan. This irreversibility is the pharmacological basis for once-daily low-dose antiplatelet dosing; no other conventional NSAID shares this property. All other NSAIDs inhibit COX reversibly through competitive or non-covalent interactions, so their effect is limited by plasma drug concentration and plasma half-life.

• Option A: Option A is incorrect. Aspirin is not a selective COX-2 inhibitor; it inhibits both isoforms with greater potency at COX-1 than COX-2 at low doses. Selective COX-2 inhibition describes celecoxib and the withdrawn coxibs, not aspirin.
• Option C: Option C is incorrect. Aspirin does have a short plasma half-life of approximately 15 to 20 minutes, but this is irrelevant to its antiplatelet duration because the inhibition is irreversible, not concentration-dependent. Describing the inhibition as competitive misidentifies the mechanism as reversible.
• Option D: Option D is incorrect. NSAIDs do not inhibit phospholipase A2; they act downstream of arachidonic acid release at the cyclooxygenase step. Corticosteroids reduce phospholipase A2 activity indirectly through annexin-1 (lipocortin) induction.
• Option E: Option E is incorrect. Aspirin does not selectively inhibit TXA2 synthase. It inhibits COX-1 and COX-2, which reduces the production of all COX-derived prostanoids including both TXA2 and prostacyclin (PGI2). Selective TXA2 synthase inhibitors are a distinct pharmacological class.

ANSWER: D

Rationale:

Prostaglandin H2 synthase (also called cyclooxygenase or COX) is a bifunctional enzyme with two catalytic activities: a cyclooxygenase activity that converts arachidonic acid to prostaglandin G2 (PGG2), and a peroxidase activity that then reduces PGG2 to prostaglandin H2 (PGH2). NSAIDs exert their primary therapeutic effect by blocking the cyclooxygenase activity — the first and rate-limiting step — preventing conversion of arachidonic acid to PGG2. PGH2 is the common precursor for all downstream prostanoids including thromboxane A2, prostacyclin, and the prostaglandin series (PGE2, PGD2, PGF2α). Blocking this step reduces the entire downstream prostanoid output, which accounts for the anti-inflammatory, analgesic, antipyretic, and antiplatelet effects of the drug class.

• Option A: Option A is incorrect. The 5-lipoxygenase (5-LOX) pathway converts arachidonic acid to leukotrienes, not prostaglandins. NSAIDs have no significant inhibitory effect on 5-LOX; the LOX pathway remains fully active during NSAID therapy, which is why aspirin-exacerbated respiratory disease occurs — arachidonic acid is redirected into the leukotriene pathway when COX is blocked.
• Option B: Option B is incorrect. Although the peroxidase activity of COX does convert PGG2 to PGH2 as the second catalytic step, NSAIDs inhibit the cyclooxygenase (first) activity, not the peroxidase activity. The peroxidase active site is distinct and is not the target of conventional NSAIDs.
• Option C: Option C is incorrect. Thromboxane synthase is a downstream enzyme that converts PGH2 to TXA2 and is located specifically in platelets and macrophages. NSAIDs do not directly inhibit thromboxane synthase; they reduce TXA2 production indirectly by blocking COX upstream.
• Option E: Option E is incorrect. Phospholipase A2 (PLA2) liberates arachidonic acid from the sn-2 position of membrane phospholipids, a step upstream of COX. NSAIDs do not inhibit PLA2; this step is inhibited indirectly by corticosteroids via annexin-1 induction.

ANSWER: A

Rationale:

The prostanoid imbalance hypothesis provides the primary mechanistic explanation for the cardiovascular hazard of selective COX-2 inhibitors. Prostacyclin (PGI2), synthesized predominantly in vascular endothelial cells via COX-2, is a potent vasodilator and inhibitor of platelet aggregation. Thromboxane A2 (TXA2), synthesized in platelets primarily via COX-1, is a potent vasoconstrictor and platelet activator. Under physiological conditions these two eicosanoids are in balance. Selective COX-2 inhibitors suppress endothelial PGI2 synthesis without inhibiting platelet COX-1 (and thus TXA2 production), creating an imbalance that favors thrombosis, vasoconstriction, and increased cardiovascular events. Non-selective NSAIDs inhibit both COX-1 and COX-2, blunting both arms of this pathway and partially preserving the balance, though they do not eliminate cardiovascular risk entirely.

• Option B: Option B is incorrect. While sodium and water retention does occur with selective COX-2 inhibitors (and contributes to elevated blood pressure), this effect is shared with non-selective NSAIDs because PGE2-mediated renal effects involve both COX isoforms. This mechanism does not explain the specifically elevated thrombotic risk distinguishing selective COX-2 inhibitors from non-selective agents.
• Option C: Option C is incorrect. NSAIDs and coxibs do not directly activate the renin-angiotensin-aldosterone system (RAAS). Reduced renal prostaglandin synthesis can blunt the vasodilatory response to RAAS activation and contribute to sodium retention, but this is an indirect and shared effect — it does not explain the differential cardiovascular risk of COX-2 selective agents.
• Option D: Option D is incorrect. Selective COX-2 inhibitors do not directly stimulate thromboxane A2 receptors. Their prothrombotic effect is mediated by reducing the opposing PGI2 signal, not by directly activating the TXA2 receptor. This option invents a receptor pharmacology not supported by the literature.
• Option E: Option E is incorrect. Arginase-mediated nitric oxide (NO) depletion is not an established mechanism of cardiovascular toxicity for selective COX-2 inhibitors. While endothelial dysfunction and reduced NO bioavailability may be associated with chronic NSAID use in some settings, the primary and best-validated mechanism for coxib cardiovascular risk is the PGI2/TXA2 prostanoid imbalance described above.

ANSWER: C

Rationale:

Ibuprofen is a reversible, competitive inhibitor of COX-1. When ibuprofen is present in the COX-1 active site, it physically occupies the channel leading to Ser530, the serine residue that aspirin must access to acetylate and irreversibly inactivate the enzyme. If ibuprofen is taken before aspirin, it blocks aspirin's access to this site; aspirin cannot acetylate a residue it cannot reach. Once ibuprofen dissociates (it is reversible), the enzyme is again functional — but aspirin has already been absorbed and cleared, so the window for irreversible acetylation has passed. The clinical consequence is near-complete attenuation of aspirin's antiplatelet effect. The interaction is timing-dependent: taking aspirin at least 30 to 60 minutes before ibuprofen (or separating doses by 8 hours) avoids the interaction by allowing aspirin to acetylate COX-1 before ibuprofen arrives.

• Option A: Option A is incorrect. Ibuprofen is not a clinically significant inhibitor of CYP2C9. Aspirin's antiplatelet effect does not depend on its plasma concentration — it is mediated by irreversible acetylation during the first pass through the portal circulation and systemically, and aspirin's short plasma half-life of approximately 15 to 20 minutes is clinically irrelevant to antiplatelet duration. This option describes a pharmacokinetic mechanism that does not apply here.
• Option B: Option B is incorrect. While protein displacement interactions are pharmacokinetically recognized, this mechanism does not explain attenuation of aspirin's antiplatelet effect. Aspirin's irreversible platelet effect is not reduced by changes in its volume of distribution or renal clearance. This option is pharmacokinetically implausible as the primary interaction.
• Option D: Option D is incorrect. Ibuprofen does not act as a direct agonist at thromboxane A2 receptors. It has no known direct platelet-activating effect; its interaction with aspirin is entirely pharmacodynamic at the COX-1 enzyme level.
• Option E: Option E is incorrect. Platelets are anucleate and cannot perform transcriptional upregulation of any enzyme, including COX-1. New COX-1 protein in the platelet pool arrives only in newly released platelets from megakaryocytes, a process that takes days — it is not a compensatory response to ibuprofen co-administration.

ANSWER: E

Rationale:

Lithium is eliminated almost entirely by renal excretion, and its clearance is closely coupled to renal sodium handling — lithium is reabsorbed in the proximal tubule alongside sodium. Renal prostaglandins, particularly PGE2 and prostacyclin (PGI2), maintain afferent arteriolar tone and glomerular filtration rate (GFR) under conditions of reduced effective circulating volume or renal stress. When NSAIDs inhibit renal COX and suppress prostaglandin synthesis, afferent arteriolar vasoconstriction ensues, GFR falls, and tubular flow decreases. In the proximal tubule, reduced flow leads to increased sodium (and lithium) reabsorption. The net result is a clinically meaningful rise in serum lithium levels that can reach the toxic range (above 1.5 mEq/L) without any change in lithium dose. This interaction is class-wide for NSAIDs and is not specific to naproxen; lithium levels should be monitored when any NSAID is initiated, dose-adjusted, or discontinued.

• Option A: Option A is incorrect. There is no clinically established renal tubular transporter for active lithium secretion that naproxen or other NSAIDs are known to competitively inhibit. Lithium handling is primarily passive reabsorption coupled to sodium, not active secretion, making competitive transporter inhibition an incorrect mechanistic explanation.
• Option B: Option B is incorrect. Lithium is not metabolized by CYP3A4 or any other cytochrome P450 isoform — it is an elemental ion and does not undergo hepatic biotransformation. Naproxen does not induce CYP3A4. This option is pharmacologically incoherent.
• Option C: Option C is incorrect. Lithium is not protein-bound in plasma; it circulates almost entirely as a free cation. Therefore protein-displacement interactions do not apply to lithium pharmacokinetics. This option incorrectly attributes protein binding behavior to a drug that has none.
• Option D: Option D is incorrect. Lithium is not glucuronidated and has no biliary excretion or enterohepatic recirculation. As an inorganic ion, it undergoes no hepatic conjugation reactions. This option invents a metabolic pathway for lithium that does not exist.

ANSWER: B

Rationale:

This is the "triple whammy" interaction, a well-characterized combination that produces AKI through convergent impairment of glomerular filtration pressure. Under normal conditions, renal prostaglandins (particularly PGE2 and prostacyclin) maintain afferent arteriolar dilation to preserve GFR, especially in states of reduced perfusion. Angiotensin II, generated by the renin-angiotensin system under reduced perfusion pressure, preferentially constricts the efferent arteriole to maintain glomerular hydraulic pressure. Diuretics reduce effective circulating volume, activating the renin-angiotensin-aldosterone system (RAAS) and making the kidney dependent on both mechanisms to sustain GFR. When NSAIDs block afferent arteriolar prostaglandin-mediated dilation and an ACE inhibitor eliminates efferent arteriolar angiotensin II-mediated constriction simultaneously in a volume-depleted patient, the transglomerular pressure gradient collapses and GFR falls precipitously. Patients with CKD, heart failure, cirrhosis, or any cause of reduced effective circulating volume are at highest risk for this interaction.

• Option A: Option A is incorrect. While lisinopril and furosemide together can increase the risk of hyperkalemia (ACE inhibition reduces aldosterone-driven potassium excretion; loop diuretics are actually kaliuretic and somewhat reduce this risk), hyperkalemia causing tubular toxicity is not the mechanism of this patient's acute kidney injury. The combination described is the prostanoid-RAAS-volume triple whammy, not a potassium-mediated toxicity.
• Option C: Option C is incorrect. Ibuprofen does not cause obstructive nephropathy through tubular crystallization of its metabolites. The acute kidney injury from NSAID use is hemodynamic (reduced GFR from loss of afferent arteriolar prostaglandin tone), not direct tubular toxic. Tubular crystallization is a nephrotoxic mechanism associated with drugs such as acyclovir, methotrexate, and indinavir — not conventional NSAIDs.
• Option D: Option D is incorrect. Furosemide-induced metabolic alkalosis does not impair renal autoregulation in the manner described. Volume depletion from furosemide does reduce renal perfusion pressure and activate the RAAS, which is correctly part of the triple whammy mechanism, but the framing of alkalosis impairing autoregulation to sensitize the kidney to prostaglandin suppression is not an established physiological mechanism.
• Option E: Option E is incorrect. Lisinopril is not metabolized by CYP3A4 — it is a prodrug hydrolyzed to lisinoprilat by intestinal and hepatic esterases, not by cytochrome P450 enzymes. This option invents a pharmacokinetic interaction pathway that does not exist for these drugs.

ANSWER: D

Rationale:

Among available NSAIDs, naproxen has consistently demonstrated the most favorable cardiovascular risk profile across epidemiological studies and meta-analyses of cardiovascular outcomes. The proposed mechanism relates to its pharmacokinetic and pharmacodynamic properties: naproxen's long half-life of approximately 12 to 17 hours and sustained COX inhibition result in more complete and sustained suppression of both COX-1-dependent TXA2 in platelets and COX-2-dependent prostacyclin (PGI2) in endothelium throughout the dosing interval. This sustained dual suppression more closely approximates the balanced inhibition of aspirin than the shorter-acting NSAIDs, which may produce intermittent prothrombotic windows when drug levels fall. The CNT (Coxib and traditional NSAID Trialists) meta-analysis confirmed that naproxen carries the lowest vascular risk among the NSAIDs studied, though it does not eliminate cardiovascular risk entirely. Current guidelines recommend naproxen for patients who require NSAID therapy and have significant cardiovascular risk.

• Option A: Option A is incorrect. Celecoxib is not thromboneutral; its selective COX-2 inhibition reduces endothelial prostacyclin while leaving platelet TXA2 intact, creating a prothrombotic imbalance. The PRECISION trial found celecoxib non-inferior to ibuprofen and naproxen for cardiovascular outcomes in a high-risk population, but this does not establish thromboneutrality, and naproxen remains preferred over celecoxib in patients with established cardiovascular disease.
• Option B: Option B is incorrect. Ibuprofen's short half-life does not confer cardiovascular protection; in fact, the intermittent inhibition pattern may create prothrombotic rebound windows when drug levels fall, and ibuprofen also blocks aspirin's antiplatelet effect when co-administered — a clinically important additional concern in patients on antiplatelet therapy.
• Option C: Option C is incorrect. Indomethacin is among the highest-risk NSAIDs for cardiovascular events in epidemiological studies and is not recommended as a cardiovascular-safe choice. Its high potency does not translate to cardiovascular protection; higher-potency non-selective COX inhibition does not improve the prostanoid balance.
• Option E: Option E is incorrect. Diclofenac exhibits preferential COX-2 activity in vivo and carries a cardiovascular risk signal in epidemiological studies comparable to selective COX-2 inhibitors — substantially higher than naproxen. It is not an appropriate choice for patients with established cardiovascular disease requiring long-term NSAID therapy.

ANSWER: A

Rationale:

Celecoxib is metabolized primarily by CYP2C9, which is responsible for the majority of its hepatic clearance, with a minor contribution from CYP3A4. Fluconazole is a potent inhibitor of CYP2C9 (as well as CYP3A4) and substantially reduces celecoxib clearance when co-administered, leading to significantly elevated celecoxib plasma concentrations. The FDA label for celecoxib recommends initiating therapy at the lowest recommended dose in patients receiving fluconazole, and close monitoring is warranted. This CYP2C9 dependence is a class-wide feature for most NSAIDs — including ibuprofen, naproxen, piroxicam, and diclofenac — making CYP2C9 inhibitors (fluconazole, amiodarone, fluvoxamine) clinically relevant interacting drugs for the entire NSAID class. Additionally, celecoxib is a moderate inhibitor of CYP2D6 (cytochrome P450 2D6), not CYP2C9, which is relevant for co-prescribed CYP2D6 substrates such as metoprolol and codeine.

• Option B: Option B is incorrect. Celecoxib does not induce CYP2C9 or any cytochrome P450 enzyme. As a CYP2C9 substrate and CYP2D6 inhibitor, celecoxib can raise concentrations of CYP2D6 substrates but does not reduce warfarin clearance through induction. The interaction concern with warfarin and NSAIDs is pharmacodynamic (additive bleeding risk through platelet inhibition and GI mucosal effects), not pharmacokinetic induction.
• Option C: Option C is incorrect. While CYP3A4 makes a minor contribution to celecoxib metabolism, CYP2C9 is the primary pathway. Describing celecoxib as metabolized exclusively by CYP3A4 is incorrect. This option would also understate the degree of fluconazole-celecoxib interaction, since fluconazole's CYP2C9 inhibition is more clinically relevant than its CYP3A4 inhibition for this combination.
• Option D: Option D is incorrect. Celecoxib is not primarily eliminated by renal tubular secretion. It undergoes extensive hepatic metabolism via CYP2C9 with renal excretion of metabolites, not intact drug. A renal transporter-mediated interaction with fluconazole is not an established mechanism for this drug pair.
• Option E: Option E is incorrect. Glucuronidation via UGT enzymes is not a primary metabolic pathway for celecoxib. Its primary route is CYP2C9-mediated oxidative metabolism. UGT-mediated glucuronidation is relevant for drugs such as morphine, lorazepam, and acetaminophen — not for celecoxib.

ANSWER: C

Rationale:

Ketorolac is a highly potent non-selective COX inhibitor available in parenteral (IM and IV) formulations, making it uniquely useful for acute pain management when oral dosing is not feasible. Its analgesic potency is comparable to moderate opioid doses — 30 mg IM ketorolac approximates 10 mg IM morphine in some acute pain models — allowing meaningful opioid-sparing in postoperative and acute pain settings. However, its potent and non-selective COX inhibition carries significant GI and renal toxicity risk that increases substantially with duration of use. Current FDA labeling restricts ketorolac use to a maximum of 5 days total (combining any oral and parenteral doses), with specific dose ceilings in elderly patients and those under 50 kg (maximum 60 mg on the first day parenterally) and in younger patients (maximum 120 mg per day parenterally). Beyond 5 days, the risk-benefit ratio shifts unfavorably and long-term use is contraindicated.

• Option A: Option A is incorrect. Parenteral administration does not eliminate GI toxicity risk for ketorolac or any non-selective NSAID. The GI mucosal injury from NSAIDs is primarily systemic — mediated by the loss of COX-1-dependent prostaglandin cytoprotection throughout the GI tract — not limited to direct topical contact with the mucosa. Parenteral ketorolac carries the same GI toxicity risk as oral formulations at equivalent doses.
• Option B: Option B is incorrect. Ketorolac is not a selective COX-2 inhibitor; it is a potent non-selective COX inhibitor with high affinity for both COX-1 and COX-2. Celecoxib is the only available selective COX-2 inhibitor in the United States. Ketorolac's high potency non-selective inhibition is the pharmacological basis for its significant GI and renal toxicity profile.
• Option D: Option D is incorrect. Ketorolac has no opioid receptor activity; it is not an opioid agonist of any type. Its opioid-sparing effect in postoperative pain management is a pharmacodynamic additive analgesic effect through a completely different mechanism — COX inhibition reducing prostaglandin-mediated peripheral and central sensitization. This complement to opioid analgesia reduces the required opioid dose without any direct opioid receptor interaction.
• Option E: Option E is incorrect. The 5-day limitation applies to all adult patients regardless of age and is based on duration-dependent toxicity risk, not an age-based contraindication for younger patients. Ketorolac's COX-1 inhibition is reversible (non-covalent), not irreversible; only aspirin irreversibly acetylates COX. A single dose of ketorolac does not cause peptic ulceration within 48 hours in healthy young adults.

ANSWER: E

Rationale:

The ductus arteriosus is maintained in a patent (open) state during fetal life primarily by prostaglandin E2 (PGE2), which acts on EP4 receptors in ductal smooth muscle to stimulate adenylyl cyclase, raise intracellular cyclic AMP (cAMP), activate protein kinase A, and cause smooth muscle relaxation and vasodilation. In full-term neonates, the postnatal rise in oxygen tension and the rapid fall in circulating PGE2 (as placental prostaglandin synthesis ceases) together trigger ductal constriction and functional closure within 24 to 48 hours. In preterm neonates, this process is impaired: ductal smooth muscle has heightened sensitivity to PGE2, and circulating PGE2 levels remain elevated. Indomethacin, as a potent non-selective COX inhibitor, reduces systemic PGE2 synthesis and removes the primary relaxing stimulus to ductal smooth muscle, allowing constriction and pharmacological closure to occur. This is an established neonatal critical care indication unique among NSAIDs to indomethacin (and ibuprofen in some protocols).

• Option A: Option A is incorrect. Adenosine receptors are not the primary mediators of ductal patency in the neonatal circulation, and indomethacin is not an adenosine receptor antagonist. Adenosine plays roles in cardiac conduction and cerebral circulation but is not the established primary vasorelaxant maintaining the ductus arteriosus in preterm neonates.
• Option B: Option B is incorrect. Indomethacin inhibits cyclooxygenase, not phosphodiesterase. PDE inhibitors (such as sildenafil and milrinone) actually raise intracellular cAMP or cGMP and tend to promote vasodilation — the opposite of the desired ductal closure effect. This option inverts the pharmacological direction of the effect.
• Option C: Option C is incorrect. Indomethacin does not stimulate endothelin-1 receptors. Endothelin-1 is a potent endogenous vasoconstrictor, but its receptor signaling is not activated by indomethacin. The drug works entirely through COX inhibition and removal of the prostaglandin vasodilatory drive.
• Option D: Option D is incorrect. Indomethacin does not inhibit nitric oxide (NO) synthase. While NO does contribute to ductal relaxation, particularly under hypoxic conditions, it is not the primary mediator of ductal patency in the neonatal setting. The established pharmacological target is the COX-PGE2 axis, not the NO pathway, and indomethacin has no known clinically relevant NOS inhibitory activity.

ANSWER: B

Rationale:

Aspirin exhibits genuine dose-dependent pharmacology that reflects the differing requirements of its therapeutic applications. At low antiplatelet doses (75–325 mg/day), aspirin efficiently and irreversibly inactivates COX-1 in platelets — a particularly sensitive target because platelets cannot synthesize new COX protein, so a single dose confers protection for the entire 8- to 10-day platelet lifespan. At analgesic and antipyretic doses (300–1,000 mg per single dose), plasma concentrations rise sufficiently to inhibit central COX activity in the hypothalamic thermoregulatory center (antipyresis) and to provide peripheral analgesic effects. At full anti-inflammatory doses (3,000–6,000 mg/day in divided doses), high and sustained plasma concentrations are required to continuously suppress COX activity in inflamed synovium and other tissues, where COX-2 expression and enzyme turnover are substantially elevated by the inflammatory milieu. The Michaelis-Menten kinetics become zero-order (saturable) at high doses, and non-linear pharmacokinetics contribute to toxicity risk at anti-inflammatory doses.

• Option A: Option A is incorrect. The antiplatelet effect of aspirin at low doses is irreversible, not reversible — this is aspirin's defining pharmacological distinction. Reversible COX-1 inhibition at low doses would imply duration limited by plasma half-life (approximately 15–20 minutes), which would make antiplatelet dosing every 24 hours ineffective. The irreversibility of the platelet effect is precisely what makes once-daily low-dose dosing pharmacologically rational.
• Option C: Option C is incorrect. This option inverts the true dose-selectivity of aspirin. At low doses, aspirin preferentially inactivates COX-1 (the platelet-dominant isoform) rather than COX-2. The threshold for COX-2 inhibition sufficient to produce anti-inflammatory effects requires higher doses. Aspirin does not selectively inhibit COX-2 at any dose — COX-2 selectivity is the property of celecoxib and the withdrawn coxibs.
• Option D: Option D is incorrect. The dose differences are not purely pharmacokinetic; they reflect genuine pharmacodynamic differences. At low doses, the irreversible platelet effect is uniquely exploited because platelets cannot replace inactivated enzyme. At anti-inflammatory doses, the pharmacodynamic target is different — rapid-turnover COX-2 in inflamed tissue requiring continuous suppression — which is a qualitatively different pharmacodynamic requirement, not merely a volume-of-distribution effect.
• Option E: Option E is incorrect. While very high concentrations of salicylates can affect NF-κB (nuclear factor-kappa B) signaling in experimental systems, this is not the established primary mechanism of aspirin's anti-inflammatory effect at clinically used doses. Anti-inflammatory doses of aspirin produce their effects primarily through COX inhibition and reduced prostaglandin synthesis in inflamed tissues. NF-κB modulation is not the accepted pharmacological explanation for the dose escalation required for anti-inflammatory efficacy.

ANSWER: D

Rationale:

The patient in option D carries three simultaneous absolute or near-absolute contraindications to NSAID therapy: an estimated GFR of 22 mL/min/1.73m² (stage 4 CKD, well below the threshold of 30 mL/min/1.73m² below which all NSAIDs should be avoided or used only with extreme caution), decompensated heart failure (where renal prostaglandins are critically needed to maintain GFR against the background of severely reduced cardiac output and activated RAAS), and active peptic ulcer disease history (high risk of GI mucosal injury). In this patient, NSAIDs eliminate the prostaglandin-dependent afferent arteriolar vasodilation that is the last buffer maintaining GFR, and any further reduction in renal function in a patient with stage 4 CKD could precipitate dialysis-dependent kidney failure. Current guidelines consistently list an estimated GFR below 30 mL/min/1.73m², decompensated heart failure, and active peptic ulcer disease as conditions where NSAIDs are contraindicated or should be used only if no alternative exists.

• Option A: Option A is incorrect. This patient has mild CKD stage 2 (GFR 72) with no other major NSAID risk factors. She is not in the high-risk category for renal, GI, or cardiovascular NSAID toxicity. At an appropriate dose and duration with monitoring, NSAIDs could be used with standard precautions; extreme caution is not required.
• Option B: Option B is incorrect. Mild hypertension well-controlled on a calcium channel blocker with a GFR of 65 mL/min/1.73m² and no GI or cardiac history represents a low-risk NSAID candidate. Blood pressure monitoring during NSAID use is appropriate, but this does not represent a contraindication requiring extreme caution comparable to the patient in option D.
• Option C: Option C is incorrect. A GFR of 58 mL/min/1.73m² (stage 3a CKD) with rheumatoid arthritis and controlled hypothyroidism warrants monitoring and preference for agents with lower renal risk (such as naproxen at the lowest effective dose), but does not independently contraindicate NSAID use at the level of stage 4 CKD or decompensated heart failure. Levothyroxine has no clinically significant interaction with NSAIDs.
• Option E: Option E is incorrect. Mild asthma without prior aspirin sensitivity, allergies, and mild overweight with normal renal and cardiovascular function do not constitute high-risk NSAID contraindications. Aspirin-exacerbated respiratory disease (AERD) requires specific prior documentation of aspirin or NSAID-triggered bronchospasm before contraindication applies; a history of asthma alone is not a contraindication, though caution is warranted.

ANSWER: A

Rationale:

Diclofenac has a well-characterized hepatotoxicity signal that distinguishes it from most other non-selective NSAIDs. It is metabolized by CYP2C9 (primary) and CYP3A4, and its biotransformation generates a reactive acyl glucuronide metabolite capable of covalently binding hepatic proteins and triggering immune-mediated hepatocellular injury. Transaminase elevations occur in up to 15% of patients receiving standard doses (75–150 mg/day), and clinically significant hepatotoxicity — defined as greater than three times the upper limit of normal for ALT (alanine aminotransferase) or AST (aspartate aminotransferase) — occurs in approximately 1–3% of patients on prolonged therapy. The FDA prescribing information recommends baseline liver function tests and periodic monitoring during long-term diclofenac therapy, with discontinuation if transaminases exceed three times the upper limit of normal. This hepatotoxicity profile is substantially greater than that of ibuprofen, naproxen, or indomethacin at equivalent doses.

• Option B: Option B is incorrect. Aplastic anemia is not an established toxicity of diclofenac. This serious hematological toxicity is associated with phenylbutazone (largely withdrawn from clinical use) and, very rarely, with indomethacin. Diclofenac's hematological adverse effect profile does not include aplastic anemia as a class-specific concern requiring routine CBC monitoring.
• Option C: Option C is incorrect. All NSAIDs require renal function monitoring in at-risk patients (reduced GFR, volume depletion, concomitant diuretics or RAAS inhibitors), but this is not a diclofenac-specific concern. Diclofenac does not undergo meaningful renal tubular secretion of intact drug in a manner that creates unique nephrotoxic accumulation; its renal risk is shared with the non-selective NSAID class and is related to afferent arteriolar prostaglandin suppression, not renal tubular concentration.
• Option D: Option D is incorrect. No established drug interaction between diclofenac and thyroid hormone transport or uptake into hepatocytes has been documented. Diclofenac does not inhibit transporters relevant to thyroid hormone metabolism at therapeutic concentrations. TSH monitoring is not a labeled requirement for diclofenac therapy.
• Option E: Option E is incorrect. Drug-induced lupus is associated with drugs such as hydralazine, procainamide, isoniazid, and minocycline — not with diclofenac. Diclofenac does not have an established mechanism for nuclear protein haptenization causing drug-induced autoimmune disease, and ANA monitoring is not indicated during diclofenac therapy.

ANSWER: C

Rationale:

Primary dysmenorrhea is driven by excessive production of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) in the secretory endometrium during the late luteal phase and early menstruation. These prostaglandins act on EP and FP receptors in uterine smooth muscle, stimulating intense myometrial contractions that exceed placental perfusion capacity and produce ischemia, which is the primary source of cramping pain. PGF2α also sensitizes peripheral nociceptors and contributes to systemic symptoms (nausea, diarrhea, back pain) through systemic absorption. NSAIDs are first-line pharmacological therapy because they inhibit COX-1 and COX-2 in the endometrium, directly reducing PGE2 and PGF2α synthesis and thereby decreasing uterine contractility, ischemia, and nociceptor sensitization. Mefenamic acid (a fenamate NSAID that also blocks prostaglandin receptors), naproxen, and ibuprofen have the best-established evidence base for primary dysmenorrhea; initiating therapy 1–2 days before expected menstrual onset and continuing through the first 2–3 days is more effective than starting at the onset of pain.

• Option A: Option A is incorrect. While combined oral contraceptives are an effective second-line treatment for primary dysmenorrhea (they reduce endometrial proliferation and prostaglandin production through suppression of the hypothalamic-pituitary-ovarian axis), the mechanism of dysmenorrhea pain is prostaglandin-driven contractility, not directly estrogen-driven endometrial proliferation per se. More importantly, NSAIDs — not oral contraceptives — are the established first-line pharmacological treatment for primary dysmenorrhea.
• Option B: Option B is incorrect. Uterine contractility in dysmenorrhea is driven by prostaglandins acting on smooth muscle prostanoid receptors, not by alpha-1 adrenergic receptor activation. Alpha-1 receptor antagonists are antihypertensive agents and are not used or indicated for primary dysmenorrhea. This option incorrectly assigns autonomic nervous system pharmacology to a prostaglandin-mediated condition.
• Option D: Option D is incorrect. While progesterone withdrawal is the trigger for increased endometrial prostaglandin synthesis at the time of menstruation, progesterone itself does not directly sensitize uterine nociceptors as the primary pain mechanism. Progesterone receptor antagonists (such as mifepristone) are not first-line or standard-of-care for primary dysmenorrhea, and this option misidentifies the pharmacological target.
• Option E: Option E is incorrect. Primary dysmenorrhea is not caused by an endorphin deficit, and low-dose opioids are not first-line or standard-of-care for this condition. Opioids are reserved for refractory cases after NSAID failure and are associated with dependence risk. The prostaglandin excess mechanism is well-established, and this option mischaracterizes both the pathophysiology and the treatment hierarchy.

ANSWER: E

Rationale:

Metoprolol is metabolized primarily by CYP2D6, which is responsible for the majority of its hepatic clearance. Celecoxib is a well-established moderate inhibitor of CYP2D6 — an enzyme interaction distinct from its CYP2C9 substrate status and its COX-2 pharmacodynamic activity. When celecoxib inhibits CYP2D6, metoprolol clearance is reduced, its plasma concentrations rise, and its beta-1 adrenergic receptor blockade in the sinoatrial node intensifies, producing clinically significant bradycardia. This interaction is particularly important in patients who are extensive CYP2D6 metabolizers (the majority of the population), whose metoprolol clearance is most dependent on CYP2D6 activity and therefore most sensitive to its inhibition. Similar CYP2D6-mediated interactions occur between celecoxib and other CYP2D6 substrates including codeine (reduced conversion to morphine, reducing analgesic efficacy) and tricyclic antidepressants (increased TCA concentrations and toxicity risk).

• Option A: Option A is incorrect. Celecoxib is not a CYP3A4 inducer and does not induce any cytochrome P450 enzyme. Additionally, metoprolol is not primarily metabolized by CYP3A4; its primary metabolic pathway is CYP2D6. The mechanism described — enzyme induction causing compensatory bradycardia — is not a recognized pharmacological phenomenon.
• Option B: Option B is incorrect. Celecoxib has no direct pharmacological activity at beta-1 adrenergic receptors. It is a COX-2 inhibitor and a CYP2D6 inhibitor; it does not interact with adrenergic receptors. Characterizing celecoxib as a sinoatrial beta-1 receptor activator misidentifies its mechanism of action entirely.
• Option C: Option C is incorrect. Celecoxib is a substrate of CYP2C9 (not an inhibitor of CYP2C9 at clinically relevant concentrations), and metoprolol is not metabolized by CYP2C9. CYP2C9 inhibition by celecoxib is not an established interaction, and even if it were, it would not affect metoprolol clearance, which is CYP2D6-dependent.
• Option D: Option D is incorrect. While NSAID-induced sodium and water retention can modestly increase blood pressure and slightly reduce reflex sympathetic activity, this is a minor hemodynamic effect that does not explain a resting heart rate drop of 14 beats per minute. The pharmacokinetic CYP2D6 interaction raising metoprolol concentrations is the established and primary explanation for clinically significant bradycardia when these two drugs are combined.

ANSWER: B

Rationale:

When a patient has both high GI risk and high cardiovascular risk, the prescribing framework from current clinical guidelines specifies that NSAIDs should be avoided altogether if possible. When NSAID use is unavoidable, the preferred strategy is naproxen at the lowest effective dose combined with a proton pump inhibitor (PPI). Naproxen is selected because it carries the most favorable cardiovascular risk profile among available NSAIDs. The PPI is added because naproxen is a non-selective NSAID that suppresses COX-1-dependent gastroprotective prostaglandins, and PPI co-therapy significantly reduces the risk of GI ulceration and bleeding in high-risk patients. This combination does not eliminate the cardiovascular risk, but it minimizes it (naproxen) while adding the most effective available GI prophylaxis (PPI). Notably, the co-administration of ibuprofen with this patient's aspirin would also impair aspirin's antiplatelet effect — an additional reason to prefer naproxen in a patient on secondary cardiovascular prevention.

• Option A: Option A is incorrect. Celecoxib alone is not appropriate for a patient with both high GI and high cardiovascular risk. While celecoxib reduces GI mucosal injury compared to non-selective NSAIDs, its selective COX-2 inhibition creates the PGI2/TXA2 prostanoid imbalance that is most prothrombotic, and it carries a cardiovascular risk profile worse than naproxen. Moreover, celecoxib's GI protection is attenuated in patients taking concomitant aspirin (as this patient does), as demonstrated in the CLASS trial.
• Option C: Option C is incorrect. Ibuprofen is not preferred over naproxen for patients with cardiovascular disease, particularly those on aspirin. Ibuprofen competitively blocks aspirin's access to the COX-1 active site and, when taken before aspirin, can abolish the antiplatelet effect that this patient relies on for secondary cardiovascular prevention. This pharmacodynamic interaction alone makes ibuprofen an inferior choice for patients on antiplatelet aspirin therapy.
• Option D: Option D is incorrect. Indomethacin has one of the highest cardiovascular and GI risk profiles among the non-selective NSAIDs and is not recommended in elderly patients or those with established cardiovascular disease. Misoprostol does provide GI mucosal protection through EP receptor-mediated cytoprotection, but the choice of indomethacin as the NSAID backbone makes this combination inappropriate for this patient. Current guidelines do not recommend indomethacin for high-risk patients when alternative agents are available.
• Option E: Option E is incorrect. Escalating aspirin to 325 mg daily in a patient with both high GI risk (prior ulcer bleeding) and high cardiovascular risk does not restore cardiovascular balance from celecoxib use and significantly increases GI bleeding risk. There is no evidence that higher aspirin doses counteract the PGI2/TXA2 imbalance from celecoxib, and increasing aspirin dose in a high GI-risk patient on an NSAID is contraindicated by current guidelines.

ANSWER: D

Rationale:

Platelets concentrate serotonin from plasma using the serotonin reuptake transporter (SERT), the same transporter that SSRIs block in presynaptic neurons. When an SSRI is taken systemically, it also blocks platelet SERT, progressively depleting platelet serotonin stores. Serotonin released from activated platelets amplifies platelet aggregation through 5-HT2A receptors and contributes to the platelet activation cascade. By depleting platelet serotonin, SSRIs impair a component of platelet hemostatic function. NSAIDs independently impair platelet function by inhibiting COX-1 and reducing TXA2 synthesis, the other major platelet activator. When these two mechanisms combine — SSRI-mediated serotonin depletion and NSAID-mediated TXA2 suppression — the result is additive impairment of platelet hemostasis at sites of GI mucosal injury. Multiple epidemiological studies and meta-analyses have confirmed that the combination of SSRIs and NSAIDs approximately doubles the GI bleeding risk compared to NSAIDs alone, beyond the background elevated bleeding risk from each drug individually.

• Option A: Option A is incorrect. Sertraline is not a clinically significant CYP2C9 inhibitor. Its primary CYP inhibitory activity is at CYP2D6 and, at higher doses, CYP3A4. Ibuprofen concentration-driven gastropathy from pharmacokinetic CYP2C9 inhibition by sertraline is not the established mechanism for this combination's elevated GI bleeding risk.
• Option B: Option B is incorrect. Sertraline does not activate serotonin 5-HT3 receptors on gastric parietal cells to stimulate acid hypersecretion. SSRIs block SERT; they do not act as agonists at serotonin receptor subtypes. The increased GI bleeding risk from SSRIs is mediated by platelet serotonin depletion and impaired hemostasis, not by acid hypersecretion.
• Option C: Option C is incorrect. The mechanism described — SSRI-mediated 5-HT2A receptor antagonism raising platelet cAMP and increasing platelet activation — is pharmacologically inverted. Serotonin acting on platelet 5-HT2A receptors amplifies platelet activation; blocking this receptor would reduce activation, not increase it. SSRIs do not function as 5-HT2A antagonists (that is the mechanism of atypical antipsychotics such as quetiapine). The actual mechanism is platelet serotonin depletion through SERT blockade.
• Option E: Option E is incorrect. Sertraline does not inhibit gastric mucosal carbonic anhydrase. This enzyme is inhibited by drugs such as acetazolamide and topiramate, not by SSRIs. There is no established mechanism by which sertraline reduces gastric bicarbonate secretion, and this option invents a pharmacological interaction that does not exist.

ANSWER: A

Rationale:

In 2020, the FDA strengthened its existing warnings on NSAID use during pregnancy to specifically address risks beginning at 20 weeks of gestation. Prostaglandins (particularly PGE2 and PGI2) play essential roles in the fetal circulation and fetal renal development. After 20 weeks, NSAID use carries two primary fetal risks: first, premature constriction or closure of the ductus arteriosus, which is normally maintained in a dilated state by prostaglandins and is required for fetal pulmonary bypass — premature constriction can cause fetal pulmonary hypertension and right ventricular failure; second, oligohydramnios, resulting from reduced fetal renal prostaglandin synthesis, which impairs fetal urine production and amniotic fluid volume, potentially causing limb contractures, delayed lung maturation, and fetal death with prolonged exposure. Use at 30 weeks or beyond carries the greatest risk of ductus arteriosus constriction and is particularly strongly warned against. For this patient at 24 weeks, ibuprofen should be avoided, and acetaminophen should be recommended instead for pain management.

• Option B: Option B is incorrect. There is no established mechanism by which NSAIDs impair fetal neuronal migration or cortical folding. While some animal data have raised questions about prostaglandin roles in CNS development, premature ductal constriction and oligohydramnios — not neurodevelopmental harm from a single dose — are the FDA-identified risks driving current warnings. This option overstates and mischaracterizes the established teratogenic profile.
• Option C: Option C is incorrect. The PGI2/TXA2 imbalance from NSAIDs affects maternal vascular physiology but the mechanism described — increased maternal platelet aggregation causing placental abruption — is not the FDA-mandated warning driving prescribing restrictions in pregnancy. The primary fetal risks (ductal constriction, oligohydramnios) are the basis for the 20-week warning. This option misidentifies the primary concern and the direction of the prostanoid effect (non-selective NSAIDs reduce TXA2 in maternal platelets, not increase it).
• Option D: Option D is incorrect. This option is incorrect in both directions. NSAIDs carry teratogenic and pregnancy risks across multiple gestational windows, not just the first trimester. First-trimester use raises concerns about miscarriage and, for aspirin at higher doses, potential cardiac defects. The specific 20-week warning addresses the distinct fetal vascular and renal risks that emerge in the second half of pregnancy.
• Option E: Option E is incorrect. Prostaglandin-dependent fetal bone mineralization impairment producing skeletal dysplasia analogous to bisphosphonate embryopathy is not an established NSAID adverse effect. NSAIDs can impair bone healing in adults through effects on osteoblast function in some experimental models, but a syndrome of fetal skeletal dysplasia from gestational NSAID use has not been documented as a clinical concern and is not part of the FDA pregnancy warning for this drug class.

ANSWER: C

Rationale:

Indomethacin is conjugated in the liver to form a glucuronide metabolite, which is excreted via bile into the intestinal lumen. In the intestine, bacterial beta-glucuronidase enzymes hydrolyze the glucuronide bond, releasing free, unconjugated indomethacin back into the intestinal lumen. This unconjugated drug is then reabsorbed from the intestine, re-enters the portal circulation, returns to the liver, and undergoes re-conjugation and re-excretion — a cycle termed enterohepatic recirculation. The pharmacokinetic consequences are twofold: first, the effective half-life and duration of action of indomethacin are prolonged beyond what the primary plasma elimination half-life alone would predict; second, the intestinal mucosa is repeatedly exposed to free indomethacin released from the glucuronide conjugate during each cycle, compounding the local COX-1 inhibition and mucosal prostaglandin depletion that contribute to GI toxicity. This property is shared by several other NSAIDs including diclofenac and sulindac (also a substrate for enterohepatic recirculation), and it is a contributing factor to the class's intestinal toxicity profile.

• Option A: Option A is incorrect. Indomethacin has high oral bioavailability (approximately 98%) — essentially complete absorption — so it does not produce high intestinal concentrations from unabsorbed drug. Its GI toxicity is not mediated by luminal contact from poor absorption; the reverse is true. This option incorrectly characterizes its bioavailability.
• Option B: Option B is incorrect. While indomethacin does have a reasonably high volume of distribution reflecting lipophilicity and tissue binding, sequestration in intestinal smooth muscle at pharmacologically active concentrations long after plasma clearance is not the established mechanism for its prolonged GI mucosal exposure. The enterohepatic recirculation cycle — not tissue sequestration — is the accepted pharmacokinetic basis for its prolonged intestinal mucosal contact.
• Option D: Option D is incorrect. Indomethacin is not actively secreted into the intestinal lumen by P-glycoprotein (P-gp) transporters. P-gp is a clinically important drug efflux transporter at the blood-brain barrier and in the intestinal epithelium, but active luminal secretion of indomethacin by P-gp is not an established pharmacokinetic mechanism contributing to its GI toxicity profile.
• Option E: Option E is incorrect. Indomethacin does not selectively induce CYP1A2 in the intestinal wall, and local generation of cytotoxic metabolites through CYP1A2 induction is not an established mechanism of indomethacin GI toxicity. The primary GI toxicity mechanisms for all NSAIDs, including indomethacin, are COX-1 inhibition with loss of gastroprotective prostaglandins plus — for indomethacin specifically — the enterohepatic recirculation loop increasing intestinal mucosal exposure.

ANSWER: E

Rationale:

The CLASS (Celecoxib Long-Term Arthritis Safety Study) trial was a large, randomized controlled trial comparing celecoxib to ibuprofen and diclofenac in patients with osteoarthritis and rheumatoid arthritis. The primary finding was that celecoxib produced significantly fewer symptomatic upper GI ulcers and ulcer complications than the non-selective NSAIDs over the trial period, consistent with the predicted GI benefit of selective COX-2 inhibition (sparing COX-1-dependent gastroprotective prostaglandins in the gastric mucosa). However, a critical finding of the trial was that the GI protective benefit of celecoxib was markedly attenuated — and in some analyses eliminated — in the approximately 20–22% of patients taking concomitant low-dose aspirin. This attenuation occurs because aspirin itself inhibits COX-1 and suppresses gastroprotective prostaglandins, negating the GI mucosal benefit that depends on COX-1 sparing. For patients on concomitant aspirin — a common clinical scenario for older adults — a PPI should be added to celecoxib to maintain meaningful GI protection. The CLASS trial did not include a cardiovascular outcome assessment as a primary endpoint.

• Option A: Option A is incorrect. The CLASS trial did not show zero GI complications with celecoxib or establish it as completely GI-safe. The trial showed a relative reduction in GI events compared to non-selective NSAIDs, with the benefit attenuated in aspirin users. Celecoxib at standard doses does not eliminate GI risk and does not eliminate the indication for gastroprotective co-therapy in high-risk patients.
• Option B: Option B is incorrect. The CLASS trial did not evaluate cardiovascular safety or compare celecoxib to placebo for cardiovascular endpoints. Cardiovascular outcomes data for celecoxib come from later studies including the PRECISION trial. Describing CLASS as establishing celecoxib's thromboneutral profile misidentifies both the trial design and its conclusions.
• Option C: Option C is incorrect. The CLASS trial was not terminated early due to excess GI bleeding with celecoxib; its findings were in the opposite direction — showing fewer GI events with celecoxib than with non-selective NSAIDs (with the aspirin-subgroup limitation). This option inverts the actual trial outcome.
• Option D: Option D is incorrect. The CLASS trial compared celecoxib to ibuprofen and diclofenac, not to rofecoxib. Rofecoxib was the comparator in the VIGOR trial, which also evaluated GI safety but used naproxen as the non-selective comparator and led to the identification of rofecoxib's cardiovascular risk. Confusing CLASS and VIGOR, or misidentifying the comparators, reflects a common but pharmacologically important error.

ANSWER: B

Rationale:

Both indomethacin and naproxen have established evidence bases for acute gout management, and for decades indomethacin was considered the canonical NSAID of choice for this indication due to its high potency and rapid achievement of anti-inflammatory synovial concentrations secondary to its lipophilicity. However, comparative evidence and clinical experience have established that indomethacin at full anti-inflammatory doses (50 mg three times daily) carries a substantially higher rate of CNS adverse effects (headache, cognitive changes, dizziness, and psychiatric symptoms in up to 10–20% of elderly patients), GI toxicity, and renal toxicity than naproxen at comparable anti-inflammatory doses. For elderly patients and those with cardiovascular or renal comorbidities — both characteristics of this 76-year-old man with CKD and hypertension — naproxen 500 mg twice daily is now the preferred NSAID for acute gout. Current prescribing guidelines including the American College of Rheumatology (ACR) recommendations reflect this preference. For patients in whom all NSAIDs carry unacceptable risk (severe CKD, decompensated heart failure), colchicine or systemic corticosteroids are the preferred alternatives.

• Option A: Option A is incorrect. This option is factually inverted — indomethacin is specifically associated with the highest rate of CNS adverse effects of any NSAID, not the fewest. Headache (paradoxically, despite its use for cluster headache prophylaxis at different doses), cognitive changes, confusion, and psychiatric symptom exacerbation are well-recognized indomethacin-specific toxicities that make it particularly problematic in elderly patients. Recommending indomethacin for elderly patients on cardiovascular safety grounds is contrary to current evidence and guidelines.
• Option C: Option C is incorrect. Ibuprofen does not have a superior evidence base for acute gout compared to naproxen or indomethacin, and a short half-life does not confer clinically meaningful renal protection in a patient with CKD who is already at elevated risk. Renal prostaglandin suppression occurs while the drug is present at therapeutic concentrations regardless of half-life; the relevant risk mitigation is agent selection and dose minimization, not half-life per se. Ibuprofen also antagonizes aspirin's antiplatelet effect, which may be relevant in elderly patients on antiplatelet therapy.
• Option D: Option D is incorrect. NSAIDs are not equally safe for acute gout regardless of patient characteristics. The choice of NSAID in acute gout is substantially influenced by the patient's age, renal function, cardiovascular risk, GI history, and concomitant medications. Stating that agent selection should be based solely on cost and preference without toxicity risk stratification is contrary to evidence-based prescribing principles.
• Option E: Option E is incorrect. Ketorolac's 5-day maximum duration limit and significant GI and renal toxicity profile do not make it an ideal choice for elderly patients with CKD. The parenteral formulation does not eliminate systemic GI toxicity risk (which is prostaglandin-mediated, not contact-dependent). Ketorolac is reserved for acute pain settings where oral dosing is not feasible, not as a preferred first-line NSAID for acute gout in outpatient elderly patients with renal impairment.

ANSWER: D

Rationale:

Most NSAIDs — including naproxen, ibuprofen, piroxicam, diclofenac, celecoxib, and meloxicam — are metabolized primarily by CYP2C9 (cytochrome P450 2C9). Amiodarone is a potent and clinically important inhibitor of CYP2C9 (as well as CYP2D6 and CYP3A4), and its inhibition of CYP2C9 substantially reduces the hepatic clearance of naproxen and other CYP2C9-substrate NSAIDs. The result is elevated naproxen plasma concentrations that can produce dose-dependent toxicity — GI symptoms (nausea, epigastric pain, dyspepsia) from enhanced COX-1-mediated gastroprotective prostaglandin suppression and renal toxicity from enhanced afferent arteriolar prostaglandin suppression — without any change in the naproxen dose. This interaction is pharmacokinetically predictable and clinically important given amiodarone's broad CYP inhibition profile and its frequent use in elderly patients with cardiovascular disease who are also likely to be taking NSAIDs. When amiodarone is initiated in a patient already on an NSAID, the NSAID dose should be reviewed and reduced if appropriate, and renal function and GI symptoms should be monitored.

• Option A: Option A is incorrect. Amiodarone is a CYP inhibitor, not a CYP inducer. It does not induce CYP3A4 or any other CYP enzyme at clinically relevant concentrations. Furthermore, naproxen is not primarily metabolized by CYP3A4; its primary pathway is CYP2C9. This option inverts the direction of the enzymatic effect and misidentifies the metabolic pathway.
• Option B: Option B is incorrect. While naproxen is highly protein-bound (greater than 99% to albumin) and protein displacement interactions are theoretically possible, clinically significant protein displacement interactions are rarely the primary mechanism of drug toxicity for highly protein-bound drugs because free drug equilibrates rapidly and the pharmacodynamic effect is buffered by tissue distribution. This option also does not accurately describe a known pharmacokinetic interaction between amiodarone and naproxen at the albumin binding site as the primary clinical concern.
• Option C: Option C is incorrect. Amiodarone does not activate P-glycoprotein (P-gp) efflux transporters; if anything, amiodarone has been described as a P-gp inhibitor (notably relevant for its interaction with digoxin). The mechanism of variable naproxen bioavailability from P-gp activation is not an established pharmacokinetic interaction for this drug pair, and naproxen already has high oral bioavailability.
• Option E: Option E is incorrect. Naproxen is not primarily eliminated by renal tubular secretion of intact drug via organic anion transporters (OATs) in a manner analogous to probenecid-methotrexate interactions. Naproxen undergoes extensive hepatic metabolism (primarily CYP2C9) followed by renal excretion of glucuronide and acyl-glucuronide metabolites. Renal tubular cytotoxicity from naproxen accumulation in tubular cells via OAT inhibition is not the established mechanism of NSAID-associated renal injury, which is hemodynamically mediated through reduced afferent arteriolar prostaglandin tone.